How Recent Executive Orders Impact the Drug Pricing Landscape

In this exclusive PC Podcast interview, Alice Valder Curran, partner at Hogan Lovells, explores how recent executive orders—both under the Biden and Trump administrations—have reshaped the drug pricing landscape, and the legal challenges or uncertainties they present for pharmaceutical companies; what life sciences companies should be doing now to proactively prepare for further executive action on drug pricing and market access; the key differences in how executive policies versus legislative actions affect the pharma industry’s pricing and commercialization strategies; the legal and strategic risks executive policy shifts pose to investors and biopharma leaders who may be planning product launches or portfolio expansion over the next few years.